The revised estimates put Wall Street's average year-end target for the S&P 500 at 6,607, implying an advance of more than 17% from Friday's close of 5,638.94, according to a recent survey of Wall ...

For investors seeking a solid return few strategies beat the classic ‘buy the dip’ approach. The idea is simple: spot a stock ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

Atlas Energy Solutions launched at Piper Sandler with an Overweight rating, attracted to multiple growth avenues, ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Piper Sandler expects the bill to pass along party lines. "Once it makes it over to the Senate, at least eight Democrats will ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

Artificial intelligence took the tech world by storm at the end of 2022, with the introduction of ChatGPT and generative AI. The past few years ...

Daner Wealth Management LLC acquired 1,081 shares of Alphabet, valued at approximately $217,000, in Q4. Institutional ...

Neivert covers the Basic Materials sector, focusing on stocks such as Methanex, Albemarle, and Celanese. According to TipRanks, Neivert has an average return of -3.6% and a 41.37% success rate on ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics ( AXSM – Research Report) today and set a price target of $148.00. The company’s shares closed yesterday at $118.78.